title: Prognostic factors and treatment outcome in non-Hodgkin's lymphoma of Waldeyer's ring.
abstract: Prognostic factors and treatment outcome of 71 patients with non-Hodgkin's lymphoma of Waldeyer's ring were analyzed retrospectively. In univariate analyses, unfavorable prognosis was associated with primary disease in the base of the tongue, stage III-IV diseases, B-symptoms, high-grade histology, T-cell phenotype, elevated serum LDH levels, decreased peripheral blood lymphocyte counts, and negative response on delayed type hypersensitivity skin reactions. Multivariate analysis showed that stage III-IV and T-cell phenotype were significant independent risk factors for death. In stage I-II lymphomas, patients with unilateral large or bilateral cervical lymph node involvement had a poorer prognosis. In stage I-II lymphomas with intermediate or high-grade histology, patients who had received radiotherapy with MTCOP-P chemotherapy (pirarubicin, cyclophosphamide, vincristine, methotrexate with leucovorin rescue, peplomycin, and predonisolone) showed significantly better 5-year disease-free survival rate compared with patients treated with radiotherapy alone.
authors.affiliation: Department of Otolaryngology, Sapporo Medical University School of Medicine, Chuo-Ku, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Harabuchi
authors.forename: H
authors.initials: H
authors.lastname: Tsubota
authors.forename: S
authors.initials: S
authors.lastname: Ohguro
authors.forename: T
authors.initials: T
authors.lastname: Himi
authors.forename: K
authors.initials: K
authors.lastname: Asakura
authors.forename: A
authors.initials: A
authors.lastname: Kataura
authors.forename: A
authors.initials: A
authors.lastname: Ohuchi
authors.forename: M
authors.initials: M
authors.lastname: Hareyama
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000704:Analysis of Variance; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D006968:Hypersensitivity, Delayed / Q000276:immunology; D007770:L-Lactate Dehydrogenase / Q000097:blood; D008198:Lymph Nodes / Q000473:pathology; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy / Q000628:therapy*; D016399:Lymphoma, T-Cell / Q000473:pathology; D008231:Lymphopenia / Q000473:pathology; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009367:Neoplasm Staging; D010641:Phenotype; D011379:Prognosis; D012189:Retrospective Studies; D012307:Risk Factors; D014062:Tongue Neoplasms / Q000473:pathology / Q000628:therapy; D014067:Tonsillar Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy / Q000628:therapy*; D016896:Treatment Outcome
chemical_list: D007770:L-Lactate Dehydrogenase